These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2339367)

  • 41. Comparison of antithrombin III assays using biological and chromogenic substrates.
    Philo RD; Gaffney PJ
    Br J Haematol; 1982 Jan; 50(1):147-56. PubMed ID: 7055531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Blood clotting diagnosis with chromogenic substrates].
    Róka L; Rasche H
    Internist (Berl); 1980 Apr; 21(4):189-94. PubMed ID: 6998907
    [No Abstract]   [Full Text] [Related]  

  • 43. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides.
    Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA
    Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.
    Bray B; Lane DA; Freyssinet JM; Pejler G; Lindahl U
    Biochem J; 1989 Aug; 262(1):225-32. PubMed ID: 2818566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
    Sandler RM; Liebman HA; Patch MJ; Teitelbaum A; Levine AM; Feinstein DI
    Cancer; 1982 Nov; 50(10):2106-10. PubMed ID: 6957257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measurement of antithrombin III in normal and pathologic states using chromogenic substrate S-2238. Comparison with immunoelectrophoretic and factor Xa inhibition assays.
    Goodnight SH; Schaeffer JL; Sheth K
    Am J Clin Pathol; 1980 May; 73(5):639-47. PubMed ID: 7377131
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III.
    Bounameaux H; Marbet GA; Lämmle B; Eichlisberger R; Duckert F
    Am J Clin Pathol; 1980 Jul; 74(1):68-73. PubMed ID: 7395817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.
    Ofosu FA; Fernandez F; Gauthier D; Buchanan MR
    Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370
    [No Abstract]   [Full Text] [Related]  

  • 50. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
    Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms of anticoagulant effects of some sulphated polysaccharides.
    Andersson LO; Hoffman J; Holmer E; Larm O; Larsson K; Söderström G
    Thromb Res; 1982 Dec; 28(6):741-7. PubMed ID: 6132465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated levels of thrombin-heparin cofactor II complex in plasma from patients with disseminated intravascular coagulation.
    Andersson TR; Sie P; Pelzer H; Aamodt LM; Nustad K; Abildgaard U
    Thromb Res; 1992 Jun; 66(5):591-8. PubMed ID: 1523613
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin.
    Ofosu FA; Sie P; Modi GJ; Fernandez F; Buchanan MR; Blajchman MA; Boneu B; Hirsh J
    Biochem J; 1987 Apr; 243(2):579-88. PubMed ID: 2443128
    [TBL] [Abstract][Full Text] [Related]  

  • 54. On the molecular-weight-dependence of the anticoagulant activity of heparin.
    Thunberg L; Lindahl U; Tengblad A; Laurent TC; Jackson CM
    Biochem J; 1979 Jul; 181(1):241-43. PubMed ID: 486155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia.
    Sas G; Blaskó G; Bánhegyi D; Jákó J; Pálos LA
    Thromb Diath Haemorrh; 1974 Sep; 32(1):105-15. PubMed ID: 4454033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evidence for essential lysines in heparin cofactor II.
    Church FC; Griffith MJ
    Biochem Biophys Res Commun; 1984 Nov; 124(3):745-51. PubMed ID: 6439196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Heparin assay in plasma. Comparison of different methods (author's transl)].
    Vinazzer H
    Anaesthesist; 1979 Jun; 28(6):299-303. PubMed ID: 464252
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Automatization of heparin determination using chronometric evaluation of anti-Xa activity of the AT III-heparin complex].
    Sampol J; Rossi JM; Lejay G
    Ann Biol Clin (Paris); 1984; 42(1):21-3. PubMed ID: 6731952
    [TBL] [Abstract][Full Text] [Related]  

  • 60. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.